Hasil Pencarian - Yasushi Goto

Perbaiki Hasil
  1. 1
    The first case of SMARCB1 (INI1) - deficient squamous cell carcinoma of the pleura: a case report

    The first case of SMARCB1 (INI1) - deficient squamous cell carcinoma of the pleura: a case report oleh Kazushi Yoshida, Yutaka Fujiwara, Yasushi Goto, Takashi Kohno, Akihiko Yoshida, Koji Tsuta, Yuichiro Ohe

    Diterbitkan 2018-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor.

    Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhib... oleh Kousuke Watanabe, Atsushi Yasumoto, Yosuke Amano, Hidenori Kage, Yasushi Goto, Yutaka Yatomi, Daiya Takai, Takahide Nagase

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Relationships among smoking habits, airflow limitations, and metabolic abnormalities in school workers.

    Relationships among smoking habits, airflow limitations, and metabolic abnormalities in school workers. oleh Masafumi Horie, Satoshi Noguchi, Wakae Tanaka, Yasushi Goto, Hisanao Yoshihara, Masaki Kawakami, Masaru Suzuki, Yoshio Sakamoto

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy

    The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy oleh Yuki Shinno, MD, Yasushi Goto, MD, PhD, Mayu Ohuchi, Akinobu Hamada, Hiroshi Nokihara, Yasuhiro Fujiwara, Yuichiro Ohe

    Diterbitkan 2020-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data.

    First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data. oleh Shoko Noda-Narita, Asuka Kawachi, Ayako Okuyama, Ryo Sadachi, Akihiro Hirakawa, Yasushi Goto, Yasuhiro Fujiwara, Takahiro Higashi, Kan Yonemori

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs

    HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs oleh Sho Watanabe, Yasushi Goto, Hiroyuki Yasuda, Takashi Kohno, Noriko Motoi, Yuichiro Ohe, Hiroyoshi Nishikawa, Susumu S. Kobayashi, Kazuyoshi Kuwano, Yosuke Togashi

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Mixed response to osimertinib and the beneficial effects of additional local therapy

    Mixed response to osimertinib and the beneficial effects of additional local therapy oleh Yuki Shinno, Yasushi Goto, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe

    Diterbitkan 2019-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Number of metastatic organs negatively affects the treatment sequence in patients with EGFR‐TKI failure

    Number of metastatic organs negatively affects the treatment sequence in patients with EGFR‐TKI failure oleh Takaaki Mizuno, Hidehito Horinouchi, Sho Watanabe, Jun Sato, Ryo Morita, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe

    Diterbitkan 2020-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer

    Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer oleh Ryota Shibaki, Shuji Murakami, Yuki Shinno, Yuji Matsumoto, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Noriko Motoi, Noboru Yamamoto, Yuichiro Ohe

    Diterbitkan 2019-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005–2014

    Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005–2014 oleh Shinichi Imafuku, Taizo Matsuki, Akiko Mizukami, Yasushi Goto, Sabrina de Souza, Céline Jégou, Veronique Bianco, Dominique Rosillon, Chie Ito, Desmond Curran, Katsiaryna Holl

    Diterbitkan 2018-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Japanese translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Japanese translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CT... oleh Tempei Miyaji, Yukiko Iioka, Yujiro Kuroda, Daigo Yamamoto, Satoru Iwase, Yasushi Goto, Masahiro Tsuboi, Hiroki Odagiri, Yu Tsubota, Takashi Kawaguchi, Naoko Sakata, Ethan Basch, Takuhiro Yamaguchi

    Diterbitkan 2017-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

    Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions oleh Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients

    Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients oleh Masahiro Torasawa, Tatsuya Yoshida, Yuki Takeyasu, Yukiko Shimoda, Akiko Tateishi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Kazuhisa Takahashi, Yuichiro Ohe

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations

    Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations oleh Yuki Takeyasu, MD, Tatsuya Yoshida, MD, Ken Masuda, MD, Yuji Matsumoto, MD, Yuki Shinno, MD, Yusuke Okuma, MD, Yasushi Goto, MD, Hidehito Horinouchi, MD, Noboru Yamamoto, MD, Yuichiro Ohe, MD

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib

    Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib oleh Yuki Takeyasu, MD, Tatsuya Yoshida, MD, Ken Masuda, MD, Yuji Matsumoto, MD, Yuki Shinno, MD, Yusuke Okuma, MD, Yasushi Goto, MD, Hidehito Horinouchi, MD, Noboru Yamamoto, MD, Yuichiro Ohe, MD

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma

    Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma oleh Yusuke Okuma, Yasushi Goto, Fumiyoshi Ohyanagi, Kuniko Sunami, Yoshiro Nakahara, Satoru Kitazono, Keita Kudo, Yuichi Tambo, Shintaro Kanda, Noriko Yanagitani, Atsushi Horiike, Hidehito Horinouchi, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Makoto Nishio, Yuichiro Ohe, Yukio Hosomi

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia

    Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia oleh Bunpei Miyazaki, Toshihide Ueno, Masanaka Sugiyama, Shinya Kojima, Ayumu Arakawa, Kayoko Tao, Kazuki Tanimura, Kouya Shiraishi, Shigehiro Yagishita, Shinji Kohsaka, Mamoru Kato, Nobutaka Kiyokawa, Yasushi Goto, Yasushi Yatabe, Akinobu Hamada, Hiroyuki Mano, Chitose Ogawa, Yosuke Tanaka

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circulating extracellular vesicles

    Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circul... oleh Masahiro Torasawa, Hidehito Horinouchi, Shigehiro Yagishita, Hirofumi Utsumi, Keitaro Okuda, Daisuke Takekoshi, Saburo Ito, Hiroshi Wakui, Saori Murata, Sawako Kaku, Kae Okuma, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Jun Araya, Yuichiro Ohe, Yu Fujita

    Diterbitkan 2023-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study

    Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study oleh Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Takao Inoue, MD, Satoshi Oizumi, MD, PhD, Shigeyuki Toyoizumi, MS, Masakazu Matsumura, MS, Rossella Messina, PharmD, PhD, Terufumi Kato, MD

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN

    First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN oleh Hidetoshi Hayashi, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Toru Kumagai, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Satoshi Oizumi, MD, PhD, Masakazu Matsumura, MS, Masayuki Okura, PhD, Gerson Peltz, MD, MPH, Terufumi Kato, MD

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: